The global montelukast intermediate market is anticipated to grow at a significant CAGR during the forecast period. The major factors responsible for the growth of the market during the forecast period include an increase in demand for the montelukast intermediate from API (Active Pharmaceutical Ingredient) manufacturers, an increase in presence of generics as well as rising prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/montelukast-intermediate-market
The montelukast intermediates are used to prevent wheezing, difficulty in breathing, chest tightness, and coughing caused by asthma. Moreover, montelukast is designated for the handling of periodic and recurrent allergic rhinitis. The important aspects pouring the market’s evolution include globally rising commonness of allergic rhinitis, urticaria, asthma, bronchospasm, burgeoning pharmaceutical industry attached with the rising call from active pharmaceutical ingredients (APIs) manufacturers, and montelukast patent expiration.
The global montelukast intermediate market analysis includes some of the key market players such as Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., and Merck & Co., Inc., among others. To maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in November 2020, Mylan received clearance from the US Federal Trade Commission (FTC) to advance the merger of Pfizer’s Upjohn generics unit.
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered
- Regions Covered- Globally
Competitive Landscape: Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., and Merck & Co., Inc., among others.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Montelukast Intermediate Market Report by Segment
By Application
- Asthma
- Allergic Rhinitis
- Bronchospasm
- Urticaria
A full report of Montelukast Intermediate Market is available at: https://www.omrglobal.com/industry-reports/montelukast-intermediate-market
Montelukast Intermediate Market– Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
- Aurobindo Pharma Ltd.
- Glenmark Pharmaceuticals Ltd.
- Merck & Co., Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
